Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Troy Z Horvat

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Annals of Pharmacotherapy|May 21, 2015
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncologyMeagan S Barbee, Adebayo Ogunniyi, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|June 5, 2015
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic LeukemiaLarry W Buie, Joshua J Pecoraro, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|January 7, 2017
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid MalignanciesAmber C King, Tim J Peterson, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|October 14, 2017
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic LeukemiaTroy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, et al.
Leukemia Research|September 16, 2016
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intoleranceTroy Z Horvat, Joshua J Pecoraro, Ryan J Daley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Annals of Pharmacotherapy|May 21, 2015
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncologyMeagan S Barbee, Adebayo Ogunniyi, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|June 5, 2015
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic LeukemiaLarry W Buie, Joshua J Pecoraro, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|January 7, 2017
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid MalignanciesAmber C King, Tim J Peterson, Troy Z Horvat, et al.
The Annals of Pharmacotherapy|October 14, 2017
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic LeukemiaTroy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, et al.
Leukemia Research|September 16, 2016
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intoleranceTroy Z Horvat, Joshua J Pecoraro, Ryan J Daley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Pageof 1